A Phase I/II Study of SEL24 in Patients With Acute Myeloid Leukemia
Phase of Trial: Phase I/II
Latest Information Update: 13 Mar 2018
At a glance
- Drugs SEL 24 (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Selvita
- 09 Mar 2018 Planned End Date changed from 1 Nov 2019 to 1 May 2020.
- 09 Mar 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Sep 2018.
- 09 Mar 2018 Status changed from active, no longer recruiting to recruiting.